Stacey Skala

Discovery of 6-Fluoro-5-(<i>R</i>)-(3-(<i>S</i>)-(8-fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4<i>H</i>)-yl)-2-methylphenyl)-2-(<i>S</i>)-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1<i>H</i>-carbazole-8-carboxamide (BMS-986142): A Reversible Inhibitor of Bruton’s Tyrosine Kinase (BTK) Conformationally Constrained by Two Locked Atropisomers

Scott H. Watterson, George V. De Lucca, Qing Shi et al. · Journal of Medicinal Chemistry · 2016 · 142 citations · Full text

Discovery of Branebrutinib (BMS-986195): A Strategy for Identifying a Highly Potent and Selective Covalent Inhibitor Providing Rapid in Vivo Inactivation of Bruton’s Tyrosine Kinase (BTK)

Scott H. Watterson, Qingjie Liu, Myra Beaudoin Bertrand et al. · Journal of Medicinal Chemistry · 2019 · 104 citations · Full text

Tyrosine Kinase, Immunology, Quantitative Pharmacology +20

The discovery of anthranilic acid-Based MMP inhibitors. Part 2: SAR of the 5-position and P11 groups

Jeremy I. Levin, J. Chen, Mingyang Du et al. · Bioorganic & Medicinal Chemistry Letters · 2001 · 75 citations · Full text

Medicinal Chemistry, Drug Target, Medicine +6

Anthranilate sulfonamide hydroxamate TACE inhibitors. Part 2: SAR of the acetylenic P1′ group

Jeremy I. Levin, J.M Chen, Mingyang Du et al. · Bioorganic & Medicinal Chemistry Letters · 2002 · 75 citations · Full text

Medicinal Chemistry, Acetylenic P1′ Group, Pharmaceutical Science +11

Bruton's tyrosine kinase inhibitor BMS-986142 in experimental models of rheumatoid arthritis enhances efficacy of agents representing clinical standard-of-care

Kathleen M. Gillooly, Claudine Pulicicchio, Mark A. Pattoli et al. · PLoS ONE · 2017 · 55 citations · Full text

Tyrosine Kinase, Immunology, Immune Regulation +22